SIRT3 and neoplasm: In vitro andin vivo characterization of SJ-106C showed that the triethylammoniumfunctional group efficiently targets SJ-106C to mitochondria and suppressesDLBCL tumor growth, further supporting the therapeutic potential ofSIRT3 inhibition in DLBCL and providing critical new insights fordeveloping improved SIRT3 inhibitors in the future.